MSLN and Hepatic fibrosis: Based on the use of an anti-mesothelin monoclonal antibody (MSLN Ab) can inhibit the transformation of mesothelial cells into fibroblasts in mouse models of liver fibrosis, as well as the transformation relationship between apCAF and mesothelial cells, researchers found that using MSLN Ab can diminish mesothelial cell to apCAF transition in vitro and in vivo.